SEHK:9926
SEHK:9926Biotechs

The Bull Case For Akeso (SEHK:9926) Could Change Following FDA Clearance Of Global Gastric Cancer Trial

Akeso has recently reported a series of oncology milestones, including FDA approval to start a global Phase III trial of cadonilimab in advanced HER2‑negative gastric cancer and new Phase II/III data on ivonescimab in triple‑negative breast cancer and squamous non‑small cell lung cancer. Together, these updates underscore Akeso’s push to position its bispecific antibodies as potential new standards of care across multiple solid tumors, supported by both efficacy and quality‑of‑life...
SEHK:9995
SEHK:9995Biotechs

Does RemeGen’s Index Debut on Shanghai’s Health Care Benchmark Reframe the Bull Case For RemeGen (SEHK:9995)?

In December 2025, RemeGen Co., Ltd was added to the Shanghai Stock Exchange Health Care Sector Index, marking its inclusion among China’s listed healthcare names tracked by this benchmark. This index inclusion can increase RemeGen’s visibility to institutional investors that track or reference sector indices, potentially influencing how the company is positioned in healthcare-focused portfolios. With this new index inclusion as a backdrop, we’ll examine how RemeGen’s expanding profile within...
SEHK:992
SEHK:992Tech

Lenovo (SEHK:992) Valuation Check After Major AI-Focused Data Infrastructure Launch

Lenovo Group (SEHK:992) just rolled out a sweeping lineup of AI ready storage, virtualization, and data management offerings, a strategic push that could gradually reshape how investors view its infrastructure and services growth story. See our latest analysis for Lenovo Group. Against that backdrop, Lenovo’s HK$9.66 share price reflects a mixed year, with recent share price returns under pressure but a solid 1 year total shareholder return of about 9.8 percent and strong three year...
SEHK:2367
SEHK:2367Personal Products

Did Giant Biogene’s New Buyback Plan Just Shift Giant Biogene Holding's (SEHK:2367) Investment Narrative?

Earlier in December, Giant Biogene Holding announced a share repurchase plan, following recent analyst coverage from Citic Securities, Citi and UBS. The buyback move is being read as a signal of management confidence and a direct attempt to enhance shareholder value. With the share repurchase plan now in place, we’ll explore how this capital allocation decision shapes Giant Biogene’s broader investment narrative. AI is about to change healthcare. These 30 stocks are working on everything...
SEHK:1983
SEHK:1983Banks

Asian Market Insights: Luzhou Bank And 2 More Promising Penny Stocks

As global markets react to interest rate adjustments and economic uncertainties, investors are increasingly looking toward alternative investment opportunities. The term 'penny stocks' might feel like a relic of past market eras, but the potential they represent is as real as ever. Typically referring to smaller or relatively new companies, these stocks can provide a mix of affordability and growth potential when paired with strong financials.
SEHK:291
SEHK:291Beverage

Assessing China Resources Beer (SEHK:291)’s Valuation After Its Corporate Governance and ESG Excellence Awards Win

China Resources Beer (Holdings) (SEHK:291) just picked up top honors in both Corporate Governance and ESG Excellence Awards, a signal that its sustainability and oversight practices are increasingly aligned with long term, risk aware investors. See our latest analysis for China Resources Beer (Holdings). At around HK$27.0, the shares have delivered an 11.34% year to date share price return. However, the 3 year total shareholder return of minus 44.69% shows the longer term momentum has been...